{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:43:55Z","timestamp":1791499435189,"version":"4.3.4"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1097\/01.cmr.0000195697.58013.b7","type":"journal-article","created":{"date-parts":[[2006,1,23]],"date-time":"2006-01-23T04:06:26Z","timestamp":1137989186000},"page":"59-64","source":"Crossref","is-referenced-by-count":18,"title":["Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-\u03b1 in patients with metastatic melanoma"],"prefix":"10.1097","volume":"16","author":[{"given":"Mar\u00eda Gonz\u00e1lez","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Malvehy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Mart\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Conill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Herrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Gasc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Begona","family":"Mellado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Castel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210129","first-page":"458","article-title":"Cutaneous melanoma","author":"Houghton","year":"1992"},{"key":"R2-9-20210129","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J Clin Oncol"},{"issue":"4","key":"R3-9-20210129","first-page":"S24","article-title":"The role of interferon alpha in the treatment of metastatic melanoma","volume":"24","author":"Legha","year":"1997","journal-title":"Semin Oncol"},{"key":"R4-9-20210129","first-page":"253","article-title":"Skin cancer, atlas of clinical oncology","author":"Gollob","year":"2001"},{"key":"R5-9-20210129","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1200\/JCO.1998.16.9.2921","article-title":"Results of interleukin-2-based treatment in advanced melanoma: a case report-based analysis of 631 patients","volume":"16","author":"Keilholz","year":"1998","journal-title":"J Clin Oncol"},{"key":"R6-9-20210129","first-page":"168","article-title":"Efficacy of interleukin-2 in the treatment of metastatic melanoma \u2013 systematic review and meta-analysis","volume":"1","author":"Allen","year":"1998","journal-title":"Cancer Ther"},{"key":"R10-9-20210129","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/BF01517207","article-title":"A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant IL-2 and interferon alpha 2a in patients with advanced malignant melanoma","volume":"38","author":"Ron","year":"1994","journal-title":"Cancer Immunol Immunother"},{"key":"R11-9-20210129","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/0959-8049(94)00459-5","article-title":"Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-\u03b1 after intravenous dacarbazine, cisplatin, carmustine and tamoxifen","volume":"31A","author":"Atzpodien","year":"1995","journal-title":"Eur J Cancer"},{"issue":"1","key":"R12-9-20210129","first-page":"S29","article-title":"Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma","volume":"3","author":"Thompson","year":"1997","journal-title":"Cancer J Sci Am"},{"key":"R13-9-20210129","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2001.19.13.3194","article-title":"Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials","volume":"19","author":"Flaherty","year":"2001","journal-title":"J Clin Oncol"},{"key":"R14-9-20210129","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/bjc.1998.214","article-title":"Randomized phase II trial of BCDT (carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen) with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma","volume":"77","author":"Johnston","year":"1998","journal-title":"Br J Cancer"},{"key":"R15-9-20210129","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1200\/JCO.1998.16.5.1752","article-title":"Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa and interleukin-2 for patients with metastatic melanoma","volume":"16","author":"Legha","year":"1998","journal-title":"J Clin Oncol"},{"key":"R16-9-20210129","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic melanoma","volume":"18","author":"Middleton","year":"2000","journal-title":"J Clin Oncol"},{"key":"R17-9-20210129","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/BF02710171","article-title":"Biochemotherapy with low doses of subcutaneous interleukin-2 in patients with melanoma: results of a phase II trial","volume":"7","author":"Gonz\u00e1lez Cao","year":"2005","journal-title":"Clin Transl Oncol"},{"key":"R18-9-20210129","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00008390-199606000-00009","article-title":"Low-dose integrated chemoimmuno-hormonotherapy with cisplatin, subcutaneous interleukin-2, alpha-interferon and tamoxifen for advanced metastatic melanoma: a pilot study","volume":"6","author":"Bernengo","year":"1996","journal-title":"Melanoma Res"},{"key":"R19-9-20210129","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/0959-8049(95)00662-1","article-title":"Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma","volume":"32A","author":"Guida","year":"1996","journal-title":"Eur J Cancer"},{"key":"R21-9-20210129","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1081\/CNV-58832","article-title":"A phase II study of biochemotherapy for advanced stage melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF","volume":"23","author":"Lewis","year":"2005","journal-title":"Cance Invest"},{"key":"R22-9-20210129","first-page":"3075","article-title":"A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, IL-2 and IFN alpha2b in patients with metastatic melanoma","volume":"8","author":"Atkins","year":"2002","journal-title":"Clin Cancer Res"}],"container-title":["Melanoma Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00008390-200602000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:08:42Z","timestamp":1785856122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00008390-200602000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.cmr.0000195697.58013.b7","relation":{},"ISSN":["0960-8931"],"issn-type":[{"value":"0960-8931","type":"print"}],"subject":[],"published":{"date-parts":[[2006,2]]}}}